Global Biopharma R&D Boasts Increased Funding, Productivity and Product Launches in 2023, says IQVIA Institute Report
This rebound occurred while clinical trial starts and funding returned to pre-pandemic levels, according to the new report, “Global Trends in R&D 2024: Activity, Productivity, and Enablers,” released by the IQVIA Institute for Human Data Science.
- This rebound occurred while clinical trial starts and funding returned to pre-pandemic levels, according to the new report, “Global Trends in R&D 2024: Activity, Productivity, and Enablers,” released by the IQVIA Institute for Human Data Science.
- “This reflects industry-wide ingenuity and regulatory acceptance of innovative data and technology-driven enablers in trial design and digital trial execution.
- R&D funding: In 2023, global funding of biopharmaceutical research and development increased to $72Bn, up from $61Bn in 2022.
- The leading deals in 2023 included 11 that were over $5Bn and were focused on cancer, neurology and cardiovascular diseases.